Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Many employers have been slow to add coverage for anti-obesity medications to their health plans, viewing them as "lifestyle" drugs despite the FDA's classification of obesity as a chronic disease
it is that the intermediary market is too concentrated to produce competitive pricing, and the contracts are opaque enough to prevent employers from auditing whether they are getting market-competitive terms
Convenient Once-Weekly Dosing: Simplify your routine with the potential for once-weekly dosing, enhancing medication adherence
Liraglutide at 3.0 mg produced mean reductions near 8% in major trials, clinically meaningful but smaller than the newer agents effects
US$ 21.34
US$ 28.55
US$ 28.70
US$ 28.95
